Antibodies Vs Alzheimer's
Add to your list(s)
Download to your calendar using vCal
If you have a question about this talk, please contact Toby Baker.
Worldwide, it is estimated that 50 million people suffer from dementia and that this number will rise to 140 millions by 2050, unless effective treatments are found. Antibodies are powerful tools in clinical research, thanks to their strong binding ability and high specificity. Dr Aprile will present how rational design and protein engineering can be used to generate antibodies as potential therapeutics for Alzheimer’s disease, the most common form of dementia.
This talk is part of the Cambridge University Biological Society series.
This talk is included in these lists:
Note that ex-directory lists are not shown.
|